Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “selinexor” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 59
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 59 pipeline programs matching "selinexor" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

59 results for “selinexor” Back to intelligence hub

Search results

Page 1 of 3
  1. SELINEXOR for endometrial cancer

    Karyopharm Therapeutics Inc

    endometrial cancer

    phase 3 small molecule active

    1 trial
  2. Selinexor

    Karyopharm Therapeutics Inc

    Dedifferentiated Liposarcoma

    phase 3 small molecule completed

    1 trial
  3. Selinexor

    Karyopharm Therapeutics Inc

    Multiple Myeloma

    phase 3 small molecule active

    12 trials
  4. Selinexor

    Karyopharm Therapeutics Inc

    Endometrial Cancer

    phase 3 small molecule active

    2 trials
  5. Selinexor (combination therapy)

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Diffuse Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial
  6. CHOP+selinexor+5-Azacitidine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Peripheral T Cell Lymphoma

    phase 2 small molecule active

    1 trial
  7. IST-342

    Karyopharm Therapeutics Inc

    Relapsed Multiple Myeloma

    phase 2 small molecule terminated

    1 trial
  8. Open Label Selinexor

    Karyopharm Therapeutics Inc

    Thymoma

    phase 2 small molecule terminated

    1 trial
  9. SELINEXOR

    Karyopharm Therapeutics Inc

    Myelofibrosis

    phase 2 small molecule active

    1 trial
  10. Selinexor

    Karyopharm Therapeutics Inc

    Myelofibrosis

    phase 2 small molecule active

    2 trials
  11. Selinexor

    Karyopharm Therapeutics Inc

    Thymoma

    phase 2 small molecule active

    1 trial
  12. Selinexor

    Karyopharm Therapeutics Inc

    Multiple Myeloma in Relapse

    phase 2 small molecule active

    1 trial
  13. Selinexor

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (Relapsed/Refractory)

    phase 2 small molecule active

    1 trial
  14. Selinexor

    Karyopharm Therapeutics Inc

    Peripheral T-cell Lymphoma (PTCL)

    phase 2 small molecule terminated

    1 trial
  15. Selinexor

    Karyopharm Therapeutics Inc

    Diabetic Foot Ulcers

    phase 2 small molecule terminated

    1 trial
  16. Selinexor

    Karyopharm Therapeutics Inc

    Glioblastoma

    phase 2 small molecule terminated

    1 trial
  17. Selinexor

    Karyopharm Therapeutics Inc

    Coronavirus Infection

    phase 2 small molecule completed

    2 trials
  18. Selinexor

    Karyopharm Therapeutics Inc

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule completed

    3 trials
  19. Selinexor

    Karyopharm Therapeutics Inc

    Acute Myeloid Leukemia (Relapsed/Refractory)

    phase 2 small molecule completed

    1 trial
  20. Selinexor

    Karyopharm Therapeutics Inc

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial
  21. Selinexor

    Karyopharm Therapeutics Inc

    Carcinoma, Neuroendocrine

    phase 2 small molecule completed

    1 trial
  22. Selinexor

    Karyopharm Therapeutics Inc

    Breast Cancer

    phase 2 small molecule completed

    1 trial
  23. Selinexor

    Hospital Authority, Hong Kong

    Acute Myeloid Leukemia, Adult

    phase 2 small molecule terminated

    1 trial
  24. Selinexor

    Karyopharm Therapeutics Inc

    Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.